Takeda Pharmaceutical Revenue 2007-2018 | TAK

Takeda Pharmaceutical annual/quarterly revenue history and growth rate from 2007 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Takeda Pharmaceutical revenue for the quarter ending December 31, 2018 was $4.445B, a 21.45% increase year-over-year.
  • Takeda Pharmaceutical revenue for the twelve months ending December 31, 2018 was $16.654B, a 7.01% increase year-over-year.
  • Takeda Pharmaceutical annual revenue for 2019 was $18.875B, a 18.45% increase from 2018.
  • Takeda Pharmaceutical annual revenue for 2018 was $15.935B, a 1.08% decline from 2017.
  • Takeda Pharmaceutical annual revenue for 2017 was $16.108B, a 7.38% increase from 2016.
Takeda Pharmaceutical Annual Revenue
(Millions of US $)
2019 $18,875
2018 $15,935
2017 $16,108
2016 $15,001
2015 $16,178
2014 $16,917
2013 $18,843
2012 $19,163
2011 $17,101
2010 $15,763
2009 $15,697
2008 $13,748
2007 $11,061
2006 $10,361
Takeda Pharmaceutical Quarterly Revenue
(Millions of US $)
Q3 2018 $4,445
Q1 2018 $4,138
Q1 2017 $4,034
Q1 2016 $4,036
Q1 2015 $3,660
Q4 2015 $3,673
Q3 2014 $4,153
Q2 2014 $4,076
Q1 2014 $4,017
Q4 2014 $3,982
Q3 2013 $4,528
Q2 2013 $4,222
Q1 2013 $4,171
Q4 2013 $3,722
Q3 2012 $4,959
Q2 2012 $4,936
Q1 2012 $5,089
Q4 2012 $4,816
Q3 2011 $5,484
Q2 2011 $4,454
Q4 2011 $4,113
Q4 2010 $3,728
Q2 2009 $2
Q4 2009 $3,594
Q4 2008 $2,839
Q4 2007 $2,525
Q4 2006 $2,371
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $27.185B $18.875B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $55.017B 35.15
Astellas Pharma (ALPMY) Japan $28.057B 13.76
UCB SA (UCBJF) Belgium $15.866B 0.00
Eisai (ESALY) Japan $15.800B 27.17
Grifols, S.A (GRFS) Spain $15.229B 19.26
Merck (MKGAF) Germany $13.816B 18.85
IPSEN SA ADR (IPSEY) France $10.783B 0.00
Ionis Pharmaceuticals (IONS) United States $9.884B 21.61
Sage Therapeutics (SAGE) United States $9.504B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $8.080B 0.00
Catalent (CTLT) United States $7.911B 31.75
Jazz Pharmaceuticals (JAZZ) Ireland $7.829B 10.73
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
STADA ARZNEIMI (STDAF) Germany $5.634B 0.00
Nektar Therapeutics (NKTR) United States $5.590B 9.11
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.420B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.938B 17.36
Evotec AG (EVTCY) Germany $4.267B 45.80
Tilray (TLRY) Canada $4.221B 0.00
FibroGen (FGEN) United States $4.109B 0.00
United Therapeutics (UTHR) United States $3.341B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.244B 11.64
Arrowhead Pharmaceuticals (ARWR) United States $2.809B 423.29
PTC Therapeutics (PTCT) United States $2.570B 0.00
Xencor (XNCR) United States $2.569B 70.14
Zogenix (ZGNX) United States $2.033B 0.00
Portola Pharmaceuticals (PTLA) United States $1.831B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.671B 80.92
Ironwood Pharmaceuticals (IRWD) United States $1.649B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.641B 22.43
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
Heron Therapeutics (HRTX) United States $1.521B 0.00
USANA Health Sciences (USNA) United States $1.461B 12.70
Corcept Therapeutics (CORT) United States $1.254B 17.90
ArQule (ARQL) United States $1.162B 0.00
Aerie Pharmaceuticals (AERI) United States $1.085B 0.00
Radius Health (RDUS) United States $1.032B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.031B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.013B 3.65
Spectrum Pharmaceuticals (SPPI) United States $0.907B 0.00
Endo (ENDP) Ireland $0.755B 1.21
Concordia (CXRXF) Canada $0.719B 0.00
Aptorum Group (APM) China $0.649B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.581B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.579B 0.00
Organogenesis Holdings (ORGO) United States $0.566B 0.00
TherapeuticsMD (TXMD) United States $0.548B 0.00
GlycoMimetics (GLYC) United States $0.513B 0.00
Karyopharm Therapeutics (KPTI) United States $0.509B 0.00
Translate Bio (TBIO) United States $0.489B 0.00
ChemoCentryx (CCXI) United States $0.481B 0.00
Siga Technologies (SIGA) United States $0.460B 1.08
Dova Pharmaceuticals (DOVA) United States $0.453B 0.00
Akebia Therapeutics (AKBA) United States $0.453B 0.00
Dermira (DERM) United States $0.452B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.445B 22.43
Catalyst Pharmaceuticals (CPRX) United States $0.426B 0.00
CV Sciences (CVSI) United States $0.421B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.416B 0.00
Flexion Therapeutics (FLXN) United States $0.415B 0.00
CannTrust Holdings (CTST) Canada $0.414B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.400B 0.00
Indivior (INVVY) United States $0.398B 1.44
MARKER THERAPEUTICS, INC (MRKR) United States $0.396B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.384B 0.00
Innate Pharma SA (IPHYF) France $0.369B 0.00
Harpoon Therapeutics (HARP) United States $0.358B 0.00
Collegium Pharmaceutical (COLL) United States $0.352B 0.00
ImmunoGen (IMGN) United States $0.345B 0.00
Xeris Pharmaceuticals (XERS) United States $0.322B 0.00
KalVista Pharmaceuticals (KALV) United States $0.304B 0.00
Rafael Holdings (RFL) United States $0.297B 0.00
Molecular Templates (MTEM) United States $0.279B 0.00
OptiNose (OPTN) United States $0.263B 0.00
Concert Pharmaceuticals (CNCE) United States $0.260B 0.00
Aratana Therapeutics (PETX) United States $0.241B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.238B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.222B 0.00
Recro Pharma (REPH) United States $0.221B 0.00
Lannett Co Inc (LCI) United States $0.221B 2.14
Ocular Therapeutix (OCUL) United States $0.208B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.189B 0.00
Nature's Sunshine Products (NATR) United States $0.175B 56.88
Redhill Biopharma (RDHL) Israel $0.172B 0.00
Calithera Biosciences (CALA) United States $0.168B 0.00
Taiwan Liposome (TLC) Taiwan $0.161B 0.00
Ardelyx (ARDX) United States $0.161B 0.00
IMV INC (IMV) Canada $0.157B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.150B 0.00
Jounce Therapeutics (JNCE) United States $0.139B 0.00
MEI Pharma (MEIP) United States $0.138B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Majesco Entertainment (PTE) United States $0.134B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.127B 0.00
Generex Biotechnology (GNBT) United States $0.110B 0.00
DURECT (DRRX) United States $0.109B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.107B 0.00
AgeX Therapeutics (AGE) United States $0.105B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
RENEURON GP (RNUGF) United Kingdom $0.098B 0.00
Infinity Pharmaceuticals (INFI) United States $0.094B 0.00
Iterum Therapeutics (ITRM) Ireland $0.093B 0.00
MediWound (MDWD) Israel $0.093B 0.00
Capnia (SLNO) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.090B 0.00
Genocea Biosciences (GNCA) United States $0.090B 0.00
Mast Therapeutics (SVRA) United States $0.090B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.089B 63.33
Aclaris Therapeutics (ACRS) United States $0.087B 0.00
Nivalis Therapeutics (ALPN) United States $0.085B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.084B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.082B 0.00
Natural Alternatives (NAII) United States $0.081B 8.08
Bellicum Pharmaceuticals (BLCM) United States $0.080B 0.00
China SXT Pharmaceuticals (SXTC) China $0.078B 0.00
Cardiome Pharma (CORV) Canada $0.077B 0.00
Otonomy (OTIC) United States $0.077B 0.00
Novan (NOVN) United States $0.072B 0.00
Neos Therapeutics (NEOS) United States $0.070B 0.00
Pharmaxis (PXSLY) Australia $0.067B 0.00
SCYNEXIS (SCYX) United States $0.065B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.060B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.056B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.052B 0.00
India Globalization Capital (IGC) United States $0.052B 0.00